619 related articles for article (PubMed ID: 18838581)
21. Surveillance and trends of antimicrobial resistance among clinical isolates of anaerobes in Kuwait hospitals from 2002 to 2007.
Jamal W; Shahin M; Rotimi VO
Anaerobe; 2010 Feb; 16(1):1-5. PubMed ID: 19406247
[TBL] [Abstract][Full Text] [Related]
22. Susceptibility trends of Bacteroides fragilis group isolates from Buenos Aires, Argentina.
Fernández Canigia L; Castello L; Di Martino A; Greco G; Legaria MC; Litterio M; Predari SC; Rollet R; Rossetti A; Carloni G; Sarchi MI; Bianchini H
Rev Argent Microbiol; 2007; 39(3):156-60. PubMed ID: 17987852
[TBL] [Abstract][Full Text] [Related]
23. Doripenem: position in clinical practice.
Dedhia HV; McKnight R
Expert Rev Anti Infect Ther; 2009 Jun; 7(5):507-14. PubMed ID: 19485791
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the in vitro activity of NVP-LMB415 against clinical anaerobic isolates with emphasis on the Bacteroides fragilis group.
Snydman DR; Jacobus NV; McDermott LA
J Antimicrob Chemother; 2005 Jun; 55(6):1024-8. PubMed ID: 15824092
[TBL] [Abstract][Full Text] [Related]
25. In vitro activities of MK-0826 and 16 other antimicrobials against Bacteroides fragilis group strains.
Betriu C; Sánchez A; Palau ML; Gómez M; Picazo JJ
Antimicrob Agents Chemother; 2001 Aug; 45(8):2372-4. PubMed ID: 11451700
[TBL] [Abstract][Full Text] [Related]
26. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms.
Jones RN; Sader HS; Fritsche TR
Diagn Microbiol Infect Dis; 2005 May; 52(1):71-4. PubMed ID: 15878447
[TBL] [Abstract][Full Text] [Related]
27. First national survey of antibiotic susceptibility of the Bacteroides fragilis group: emerging resistance to carbapenems in Argentina.
Fernández-Canigia L; Litterio M; Legaria MC; Castello L; Predari SC; Di Martino A; Rossetti A; Rollet R; Carloni G; Bianchini H; Cejas D; Radice M; Gutkind G;
Antimicrob Agents Chemother; 2012 Mar; 56(3):1309-14. PubMed ID: 22232282
[TBL] [Abstract][Full Text] [Related]
28. [Antimicrobial activity of ornidazole and 6 other antibiotics against anaerobic bacteria].
Alados JC; Martínez-Brocal A; Miranda C; Rojo MD; García V; Domínguez MC; de la Rosa M
Enferm Infecc Microbiol Clin; 1991 Apr; 9(4):219-22. PubMed ID: 1863621
[TBL] [Abstract][Full Text] [Related]
29. [Susceptibility of strict anaerobic bacteria to antibiotics in France: a multicenter study].
Grollier G; Mory F; Quentin C; Girard-Pipau F; Tigaud S; Sedallian A; Dubreuil L
Pathol Biol (Paris); 1994 May; 42(5):498-504. PubMed ID: 7824321
[TBL] [Abstract][Full Text] [Related]
30. Doripenem monohydrate, a broad-spectrum carbapenem antibiotic.
Matthews SJ; Lancaster JW
Clin Ther; 2009 Jan; 31(1):42-63. PubMed ID: 19243706
[TBL] [Abstract][Full Text] [Related]
31. In vitro activity of 11 antibiotics against 74 anaerobes isolated from pediatric intra-abdominal infections.
Goldstein EJ; Citron DM; Vaidya SA; Warren YA; Tyrrell KL; Vreni Merriam C; Fernandez H
Anaerobe; 2006 Apr; 12(2):63-6. PubMed ID: 16701615
[TBL] [Abstract][Full Text] [Related]
32. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
[TBL] [Abstract][Full Text] [Related]
33. Antimicrobial susceptibility of anaerobic bacteria in Sweden in 1983.
Nord CE; Olsson-Liljequist B
Scand J Infect Dis Suppl; 1984; 43():44-9. PubMed ID: 6100139
[TBL] [Abstract][Full Text] [Related]
34. Emergence of carbapenem resistance in Bacteroides fragilis in China.
Gao Q; Wu S; Xu T; Zhao X; Huang H; Hu F
Int J Antimicrob Agents; 2019 Jun; 53(6):859-863. PubMed ID: 30831235
[TBL] [Abstract][Full Text] [Related]
35. Doripenem.
Paterson DL; Depestel DD
Clin Infect Dis; 2009 Jul; 49(2):291-8. PubMed ID: 19527173
[TBL] [Abstract][Full Text] [Related]
36. In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
Tanaka K; Mikamo H; Nakao K; Ichiishi T; Goto T; Yamagishi Y; Watanabe K
Antimicrob Agents Chemother; 2009 Jan; 53(1):319-22. PubMed ID: 18955522
[TBL] [Abstract][Full Text] [Related]
37. [Antibiotic sensitivity of anaerobic bacteria isolated during one year (1993)].
Durán MT; Molina F
Enferm Infecc Microbiol Clin; 1996; 14(6):370-6. PubMed ID: 8756216
[TBL] [Abstract][Full Text] [Related]
38. Antimicrobial Susceptibility Patterns of Anaerobic Bacterial Clinical Isolates From 2014 to 2016, Including Recently Named or Renamed Species.
Byun JH; Kim M; Lee Y; Lee K; Chong Y
Ann Lab Med; 2019 Mar; 39(2):190-199. PubMed ID: 30430782
[TBL] [Abstract][Full Text] [Related]
39. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers.
Fuchs PC; Barry AL; Brown SD
Antimicrob Agents Chemother; 2001 Jun; 45(6):1915-8. PubMed ID: 11353653
[TBL] [Abstract][Full Text] [Related]
40. Susceptibility of anaerobic bacteria in Auckland: 1991-1996.
Shore KP; Pottumarthy S; Morris AJ
N Z Med J; 1999 Nov; 112(1099):424-6. PubMed ID: 10678225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
